TRIM21 and breast carcinoma: Anti-Ro52 is reportedly significantly increased in ovarian cancer patients and can be used as a marker to indicate better outcomes in such patients (11); antinuclear antibody positive breast cancer patients have prolonged survival after treatment, and the risk of disease recurrence and metastasis is low (10, 30); the presence of autoantibodies prolongs the progression-free survival of advanced non-small cell lung cancer patients (31) and so can be used as a prognostic factor for these patients (32).